B+
Bull case
30%
Probability
Target price
$45.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
MLYS
Mineralys TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Approval followed by effective payer access and prescribing could turn lorundrostat into a meaningful hypertension franchise. The scheduled OSA, CKD, and long-term extension presentations offer nearer-term evidence checks, not confirmed new indications.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -0.9.
What can break
At June 30, cash, cash equivalents and investments were $661.4 million, but commercialization spending, secured debt, and remaining Tanabe commercial milestones complicate the funding and economics picture [#SEC-8K-2026-08-11].
Momentum
14
Value
41
Sentiment
95
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $26.00 · Bull $45.00 · Bear $12.00Analysis 2026-10-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $46.33
Why
Momentum14 · Δ7d -0.0
Value41 · Δ7d -0.1
Sentiment95 · Δ7d -0.9
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -0.9.
Contradictions & invalidation
- • At June 30, cash, cash equivalents and investments were $661.4 million, but commercialization spending, secured debt, and remaining Tanabe commercial milestones complicate the funding and economics picture [#SEC-8K-2026-08-11].
- • FDA review could be delayed or the pivotal evidence judged insufficient; the December 22 date is a target [#SEC-8K-2026-08-11].
- • An FDA delay or rejection would sharply impair a single-asset thesis.
Catalyst clock
2026-10-08
Explore-OSA and hypertension data presentation
Lead driver: Sentiment · See AI snapshot
Momentum
14
8% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-25.9
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
95
45% active weight
Current posture
7d trendSoftening
Δ7d
-0.9
Δ21d
+6.9
Why this grade
Composite grade A. Momentum 13.5 / Value 40.6 / Sentiment 95.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$26.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$1.82B
Beta
-
Shares Out
88.41M
P/E (TTM) · Derived
-9.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-11.81
Rev YoY
-
EPS YoY
+330.3%
Gross Margin
-
Op Margin
-
Net Debt
-$656.64M
Current Ratio
34.46
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data